Susquehanna International Group
HELX icon

Susquehanna International Group’s Franklin Genomic Advancements ETF HELX Stock Holding History

Susquehanna International Group’s Portfolio HELX Stock Details HELX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Buy
+38,272
New +$1.33M ﹤0.01% 7111
2024
Q2 		– Sell
-6,934
Closed -$227K – 12513
2024
Q1 		$227K Sell
6,934
-582
-8% -$18.2K ﹤0.01% 10333
2023
Q4 		$229K Buy
+7,516
New +$209K ﹤0.01% 10395

Other funds holding HELX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group's HELX Position: Q2 2026 in Review

Susquehanna International Group opened a new position in Franklin Genomic Advancements ETF (HELX) in Q2 2026: 38,272 shares worth $1.53M. The stake represents ﹤0.01% of the portfolio and ranks #7111 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in HELX as recently as Q1 2024.

Susquehanna International Group first reported a position in HELX in Q4 2023 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold HELX as of Q2 2026.

  • Susquehanna International Group held 38,272 shares of Franklin Genomic Advancements ETF worth $1.53M as of Q2 2026.
  • Franklin Genomic Advancements ETF was a new Susquehanna International Group position in Q2 2026.
  • Franklin Genomic Advancements ETF made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #7111 holding.
  • Susquehanna International Group first reported a position in Franklin Genomic Advancements ETF in Q4 2023 and has held it in 3 quarters since.
  • 6 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.